Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
A Pilot Investigation to Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancer
M.D. Anderson Cancer Center
1,000 participants
Jun 18, 2019
OBSERVATIONAL
Conditions
Summary
This study is to find out how well liquid biopsies work as a non-invasive alternative to other methods of finding cancer cells (such as a tissue biopsy) in patients with endometrial cancer. A liquid biopsy is a blood test that may be able to find cancer cells. Collecting and storing samples of blood and tissue from patients with endometrial cancer to study in the laboratory may help doctors learn how the cells in the blood may change during treatment for uterine cancer.
Eligibility
Inclusion Criteria4
- Women age 18 years and older
- Histologic diagnosis of endometrial cancer
- Candidate for primary surgical treatment or has recently had prior primary surgery
- Willing and able to provide informed consent
Exclusion Criteria1
- Patients who have received prior treatment including chemotherapy or radiation therapy for endometrial cancer. Patients with prior primary surgery will be allowed to enroll in this trial if the patient has not received any chemotherapy or radiation at the time of enrollment. Note: patients with a history of other cancers may be enrolled after discussion with the PI if it is determined that they are at low risk for recurrence or metastasis.
Interventions
Undergo collection of blood and tissue samples
Undergo liquid biopsy
Undergo Pap smear
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05049538